Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMXF9DM)

Drug Name
OXB-102 Drug Info
Synonyms AXO-Lenti-PD
Indication
Disease Entry ICD 11 Status REF
Parkinson disease 8A00.0 Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DMXF9DM

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Aromatic-L-amino-acid decarboxylase (DDC) TTN451K DDC_HUMAN Not Available [2]
GTP cyclohydrolase-I (GCH1) TTLSWP6 GCH1_HUMAN Not Available [2]
Tyrosine 3-monooxygenase (TH) TTUHP71 TY3H_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Tyrosine 3-monooxygenase (TH) DTT TH 2.322 2.233 2.036 2.07
Aromatic-L-amino-acid decarboxylase (DDC) DTT DDC 7.255 7.312 8.596 9.191
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Parkinson disease
ICD Disease Classification 8A00.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tyrosine 3-monooxygenase (TH) DTT TH 9.10E-04 -2.73 -1.55
Aromatic-L-amino-acid decarboxylase (DDC) DTT DDC 7.84E-03 -1.49 -1.01
GTP cyclohydrolase-I (GCH1) DTT GCH1 3.38E-02 -1.59 -1.53
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03720418) Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson's Disease (SUNRISE-PD). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Oxford BioMedica.